ProtoKinetix President and CEO to be Interviewed Live

ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com), to be showcased with a live interview on Stock Plays Online today at 10:00 AM, Eastern Standard Time. This unpaid forum can be viewed at www.stockplaysonline.com with Chuck Lane. Ross Senior will address shareholders and other interested investors on the commercial rollout of the Company.

To date, ProtoKinetix has been concentrating on a partnering program to exploit the enormous potential benefits of their family of AAGP™ molecules. Having successfully entered into their first commercial joint venture agreement, the Company is positioned to aggressively pursue other inflammatory disease specific applications.

We are aware of the phenomenal disconnect between the Company’s current level of business development and today’s stock price and trading patterns. ProtoKinetix intends to remedy this situation.

About ProtoKinetix, Inc.

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX’s primary focus is on the therapeutic potential for AAGP™ in the treatment of Diabetes, inflammatory diseases, skin protection and anti-aging.

Ross L. Senior, President and CEO

Company Office:
ProtoKinetix Inc
Suite # 1500-2225 Folkestone Way
West Vancouver, BC
V7S 2Y6

Investor Contact:
604-926-6627
Email: info@protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.